Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Sermorelin vs ipamorelin (ipamorelin vs sermorelin)

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Verdict: favors sermorelin

Sermorelin has the stronger case: it was once FDA approved (Geref), it has small human trials showing higher growth hormone and IGF-1, and many 503A pharmacies still compound it because FDA found the approval was not withdrawn for safety reasons. Ipamorelin has no human trial for any growth hormone use, only one small IV pharmacology study showing growth hormone release in healthy men; its only randomized human trial, for postoperative ileus, found no benefit, and it has no federal basis for compounding after its 2023 Category 2 listing and withdrawn 503A nomination. They act on different receptors, and both are prohibited in sport.

Verified: Verified Sep 30, 2026

Which is better, sermorelin or ipamorelin?

Both are graded human RCT, but sermorelin's small studies measured growth hormone and growth (a 19 person, 16 week adult trial and pediatric growth data behind its former approval), and it has a defensible compounding pathway. Ipamorelin's one randomized trial tested intravenous dosing after bowel surgery and found no benefit, no randomized trial has tested its marketed uses, and it sits outside every 503A compounding category after its 503A nomination was withdrawn, while ipamorelin acetate remains in 503B Category 2. Neither has evidence for adult fat loss, muscle gain, or anti-aging, so the win is about evidence quality and legality, not a proven benefit. [1] [2] [6] [7] [9] [10] [12]

How do sermorelin and ipamorelin compare?

Sermorelin and Ipamorelin compared by dimension
DimensionSermorelinFavoredIpamorelin
Mechanism [3] [7] [8]GHRH receptor agonist: the first 29 amino acids of growth hormone releasing hormone, acting upstream on pituitary somatotrophs.Ghrelin receptor (GHS-R1a) agonist: a five amino acid growth hormone secretagogue acting through a separate pathway from GHRH.
Note: Because the receptors differ, the two are often marketed together, but no human trial has tested the combination.
Evidence grade [1] [6] [7] [12]Human RCT (small): single blind, placebo controlled 16 week trial in 19 adults aged 55 to 71 raised nocturnal GH and IGF-1.Human RCT: one randomized, double blind, placebo controlled trial (117 adults, intravenous, postoperative ileus) found no significant benefit. No randomized trial for its marketed uses, where the data are GH release in rats and pigs and one infusion study in healthy men.
Human outcomes measured [1] [2] [6]Higher IGF-1 and skin thickness in both sexes; lean mass and insulin sensitivity gains in men only; sleep unchanged. Children with short stature grew 7.2 versus 4.8 cm per year.Time to first tolerated meal after bowel surgery 25.3 versus 32.6 hours on placebo (p = 0.15). No human GH, IGF-1, or body composition outcome published for subcutaneous use.
Hormonal selectivity [5] [7]Response limited by somatostatin tone and pituitary capacity, so GH cannot reach levels seen with injected recombinant GH.In animals it released GH without raising ACTH, cortisol, prolactin, LH, FSH, or TSH, even at 200 times the GH ED50.
Regulatory history [9] [10]Approved as Geref (diagnostic 1990, pediatric GH deficiency 1997); discontinued, approvals withdrawn in 2009; FDA determined in 2013 the withdrawal was not for safety or effectiveness.Never approved anywhere. Placed on the 503A Category 2 list in September 2023; 503A nominations withdrawn in 2024 and listed as a withdrawn 503A nomination in the April 2026 update.
Compounding status [9] [10]Not on Category 2 or the bulks list; many 503A pharmacies compound it on the basis of the former approval, a reading that depends on the state board.No active nomination, not on the bulks list, not an approved drug component: no federal basis for 503A or 503B compounding.
Literature dosing [1] [4] [6]Geref label: 30 ug/kg subcutaneously at bedtime in children; adult trial used 10 ug/kg nightly for 16 weeks.Not established for GH use; the only human trial used 0.03 mg/kg intravenously twice daily for up to 7 days after surgery.
Typical cost [9] [10] [13]Compounded only, paid in cash through telehealth clinics that include the visit; there is no branded product. Dated prices are on the sermorelin cost page.Not available through licensed channels; ipamorelin is not on the 503A bulks list.
Note: Prices at the verification date. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

Sermorelin and Ipamorelin: grade, status, and cost
AttributeSermorelinIpamorelin
ClassSynthetic 29 amino acid N-terminal fragment of human growth hormone releasing hormone (GHRH 1-29), the shortest fragment with full GHRH receptor activitySynthetic pentapeptide growth hormone secretagogue; selective agonist at the ghrelin receptor (GHS-R1a)
What it isFormerly FDA approved piece of growth hormone releasing hormone (Geref, withdrawn 2009 for business reasons); small trials show higher GH and IGF-1.Growth hormone releaser acting on the hunger hormone (ghrelin) receptor; its one randomized placebo controlled trial, after bowel surgery, found no benefit.
EvidenceEvidence: Human RCT evidenceEvidence: Human RCT evidence
FDA statusRegulatory: Former FDA approval (Geref)Regulatory: Nomination withdrawn
CompoundingThere is no currently marketed sermorelin product in the United States. FDA approved Geref (sermorelin acetate) under NDA 19-863 in 1990 and NDA 20-443 in 1997. The sponsor discontinued both in 2008, and FDA withdrew the approvals effective June 18, 2009. In March 2013 FDA determined that Geref was not withdrawn from sale for reasons of safety or effectiveness. Sermorelin is not on the 503A bulks list and does not appear in any 503A nomination category or on FDA's withdrawn list. Many 503A pharmacies compound it on the basis that it is a component of a previously approved drug. FDA's 503B nomination list places sermorelin acetate in Category 1 and marks it as a component of FDA approved drugs. FDA has not issued a 503A-specific ruling on it, so check with the dispensing pharmacy on the basis it relies on. Using sermorelin for adult anti-aging, fat loss or sleep is an unapproved use.Not FDA approved for any use. Ipamorelin was nominated for the 503A bulks list and placed in Category 2. FDA cited immunogenicity risk from aggregation or peptide related impurities, unnatural amino acids that complicate characterization, and a published report of serious adverse events, including a death, when it was given intravenously. On October 29, 2024 the Pharmacy Compounding Advisory Committee voted against adding ipamorelin free base or ipamorelin acetate to the 503A bulks list. FDA now lists ipamorelin acetate among 503A nominations withdrawn by the nominators, which puts it in no 503A category and outside FDA's interim policy. Ipamorelin acetate also remains in 503B Category 2, added September 29, 2023. It is not on the 503A bulks list, so as of the last verification date neither 503A pharmacies nor 503B outsourcing facilities have a federal basis to compound it.
WADAWADA: WADA prohibitedWADA: WADA prohibited
RoutesSubcutaneous injection, usually at bedtime (approved and trial use), Intravenous bolus (former diagnostic use), Intranasal (research only, lower bioavailability), Oral tablets and troches sold by some compounders have no published pharmacokinetic dataSubcutaneous injection (as sold, no human pharmacokinetic publication), Intravenous infusion (human ileus trial), Intranasal (anti-doping metabolite study only)
Typical costAbout 105 to 180 USD per month for compounded sermorelin through licensed telehealth programs, including the consultation and medication. Research chemical products sold for human use are unapproved drugs. Prices checked 2026-09-22 on published provider and pharmacy price pages.Not available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Last verified

Has sermorelin been tested directly against ipamorelin?

No published trial has compared sermorelin and ipamorelin directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do sermorelin and ipamorelin cost?

Typical cost of Sermorelin and Ipamorelin
DimensionSermorelinIpamorelin
Typical cost$105 to $180 per monthNot available through licensed channels. Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.
Price detailSermorelin price by channelIpamorelin price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the Sermorelin page and the Ipamorelin page.

Are sermorelin and ipamorelin combined?

Sermorelin and ipamorelin are sold together in the premixed blend below. No study has tested the combination, and a mix is only as lawful as its least lawful ingredient. The blend page covers what is in each product, the evidence for each ingredient, and legal status.

Frequently asked questions

Which has better evidence, sermorelin or ipamorelin?

Sermorelin. It has small human trials showing higher GH and IGF-1 (including a 16 week adult trial) and pediatric growth data that supported its former FDA approval. Ipamorelin has no human trial for any GH related use, only one small IV pharmacology study showing growth hormone release in healthy men; its only randomized human trial, for postoperative ileus, was negative. [1] [2] [6] [12]

Can a pharmacy legally compound either one?

Sermorelin is widely compounded by 503A pharmacies on the basis of its former approval, which FDA confirmed was not withdrawn for safety reasons, though acceptability depends on the state board. Ipamorelin has no federal basis to be compounded: its 503A nomination was withdrawn after a 2023 Category 2 listing and it is not on the bulks list. [9] [10]

Does either help with fat loss or muscle gain?

Not on current evidence. Sermorelin's adult trial found a small lean mass gain in men only and no change in women; ipamorelin has never been tested for body composition in humans. [1] [6]

Why are they often sold together?

They stimulate GH through different receptors (GHRH versus ghrelin), and reviews of the GHRP class describe synergy with GHRH on GH release. No trial has tested sermorelin and ipamorelin together, so the benefit and safety of the combination are unknown. [7] [8]

Are they allowed in sport?

No. Both are prohibited at all times under WADA section S2: sermorelin as a GHRH analog and ipamorelin as a growth hormone secretagogue. [11]

Conditions studied

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Khorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. J Clin Endocrinol Metab 1997PubMed 9141536, 1997
  2. [2]Kirk JM et al. Treatment with GHRH(1-29)NH2 in children with idiopathic short stature induces a sustained increase in growth velocity. Clin Endocrinol (Oxf) 1994PubMed 7955460, 1994
  3. [3]Vance ML et al. The effect of intravenous, subcutaneous, and intranasal GH-RH analog, [Nle27]GHRH(1-29)-NH2, on growth hormone secretion in normal men: dose-response relationships. Clin Pharmacol Ther 1986PubMed 3096623, 1986
  4. [4]Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs 1999PubMed 18031173, 1999
  5. [5]Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging 2006PubMed 18046908, 2006
  6. [6]Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014PubMed 25331030, 2014
  7. [7]Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998PubMed 9849822, 1998
  8. [8]Camanni F, Ghigo E, Arvat E. Growth hormone-releasing peptides and their analogs. Front Neuroendocrinol 1998PubMed 9465289, 1998
  9. [9]Federal Register, March 4, 2013: Determination that Geref (sermorelin acetate) injection was not withdrawn from sale for reasons of safety or effectiveness (NDA 19-863 and NDA 20-443)Federal Register, 2013
  10. [10]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (503A bulks list, Category 1, 2, and 3 lists, and withdrawn nominations)FDA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, September 30). Sermorelin vs ipamorelin: evidence, cost, and legality. https://peptideagent.ai/compare/sermorelin-vs-ipamorelin
HTML link
<a href="https://peptideagent.ai/compare/sermorelin-vs-ipamorelin">Sermorelin vs ipamorelin: evidence, cost, and legality</a>, PeptideAgent, updated September 30, 2026.